Transforma Bio
TransformaBio, Inc. (formerly known as Nano PharmaSolutions) is a clinical-stage biotechnology company developing innovative drug delivery technologies through its proprietary NanoTransformer® platform. The company's solvent-free, scalable nanotechnology enables targeted delivery of challenging drug molecules for oral, intranasal, topical, and biomaterial applications. TransformaBio is advancing programs in neurotrauma, neurodegenerative disease, dermatology, and regenerative medicine, including the development of an intranasal neuroprotective therapy for traumatic brain injury with potential battlefield applications. The company partners with government, academic, and industry organizations to accelerate innovative medical solutions for both military and civilian patients. The migration of the website from Nanopharmasolutions.com to its new website transformabio.com will be in August 2026.
Industries
N/A
Nr. of Employees
small (1-50)
Transforma Bio is currently seeking investment
Transforma Bio is seeking a series-a investment in the range of 5m-20m
Products
NT-401 Drug-Device Combination
NT-401 is an intranasal nanoformulated riluzole developed for rapid neuroprotection following traumatic brain injury (TBI). Leveraging TransformaBio's proprietary NanoTransformer® platform, NT-401 is designed to enable early, needle-free administration during the critical "golden hour" to reduce secondary neuronal injury. The program supports both military and civilian trauma care through rapid field deployment and improved brain drug delivery.
NT-901 Drug-Device Combination
NT-901 is an investigational intranasal analgesic developed for rapid pain management following combat and civilian trauma. Utilizing the NanoTransformer® platform, NT-901 is designed for needle-free administration during prolonged field care and other austere environments where rapid, effective analgesia is critical.
NT-401 Drug-Device Combination
NT-401 is an intranasal nanoformulated riluzole developed for rapid neuroprotection following traumatic brain injury (TBI). Leveraging TransformaBio's proprietary NanoTransformer® platform, NT-401 is designed to enable early, needle-free administration during the critical "golden hour" to reduce secondary neuronal injury. The program supports both military and civilian trauma care through rapid field deployment and improved brain drug delivery.
NT-901 Drug-Device Combination
NT-901 is an investigational intranasal analgesic developed for rapid pain management following combat and civilian trauma. Utilizing the NanoTransformer® platform, NT-901 is designed for needle-free administration during prolonged field care and other austere environments where rapid, effective analgesia is critical.
Expertise Areas
- Intranasal Drug Delivery, Nanomedicine, Traumatic Brain Injury, Neuroprotection, Drug Delivery, Medical Countermeasures, Battlefield Medicine, Formulation Development
Key Technologies
- Core Platform=NanoTransformer® Technology, Nanoparticle Drug Delivery, GMP Manufacturinlogy Transfer, Scale-Up, Clinical Translation, Intranasal Drug Delivery, Nose-to-Brain Drug Delivery
Key People
News & Updates
TransformaBio, Inc. was recognized as a 2026 San Diego Business Impact Award recipient for its innovation in nanomedicine and commitment to advancing patient-centric drug delivery technologies.
Nano PharmaSolutions officially became TransformaBio, reflecting the company's evolution into a clinical-stage biotechnology company with a validated NanoTransformer® platform and a diversified pipeline spanning neurology, dermatology, regenerative biomaterials, and strategic industry partnerships.
TransformaBio, Inc. was recognized as a 2026 San Diego Business Impact Award recipient for its innovation in nanomedicine and commitment to advancing patient-centric drug delivery technologies.
Nano PharmaSolutions officially became TransformaBio, reflecting the company's evolution into a clinical-stage biotechnology company with a validated NanoTransformer® platform and a diversified pipeline spanning neurology, dermatology, regenerative biomaterials, and strategic industry partnerships.